AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More
Novartis is a 76% subsidiary of Novartis AG - Switzerland and has a countrywide presence in the healthcare business. While pharmaceuticals contributes 70% to total revenues (FY10), generics (6%), consumer healthcare i.e. OTC (14%) and animal health (... More
ASTRAZENECA PHARMA | NOVARTIS | ASTRAZENECA PHARMA/ NOVARTIS |
|||
---|---|---|---|---|---|
P/E (TTM) | x | 129.2 | 1,964.2 | 6.6% | View Chart |
P/BV | x | 39.5 | 26.1 | 151.6% | View Chart |
Dividend Yield | % | 0.0 | 1.7 | - |
![]() ![]() |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
ASTRAZENECA PHARMA Mar-18 |
NOVARTIS Mar-19 |
ASTRAZENECA PHARMA/ NOVARTIS |
5-Yr Chart Click to enlarge
|
||
High | Rs | 1,278 | 980 | 130.4% | |
Low | Rs | 883 | 600 | 147.1% | |
Sales per share (Unadj.) | Rs | 228.4 | 198.7 | 114.9% | |
Earnings per share (Unadj.) | Rs | 10.4 | 21.0 | 49.4% | |
Cash flow per share (Unadj.) | Rs | 16.3 | 22.3 | 73.1% | |
Dividends per share (Unadj.) | Rs | 0 | 10.00 | 0.0% | |
Dividend yield (eoy) | % | 0 | 1.3 | 0.0% | |
Book value per share (Unadj.) | Rs | 98.8 | 307.5 | 32.1% | |
Shares outstanding (eoy) | m | 25.00 | 24.69 | 101.3% | |
Bonus/Rights/Conversions | - | - | - | ||
Price / Sales ratio | x | 4.7 | 4.0 | 119.0% | |
Avg P/E ratio | x | 104.2 | 37.7 | 276.6% | |
P/CF ratio (eoy) | x | 66.4 | 35.5 | 187.1% | |
Price / Book Value ratio | x | 10.9 | 2.6 | 425.7% | |
Dividend payout | % | 0 | 47.7 | 0.0% | |
Avg Mkt Cap | Rs m | 27,008 | 19,508 | 138.4% | |
No. of employees | `000 | 1.4 | 0.6 | 233.4% | |
Total wages/salary | Rs m | 1,535 | 1,171 | 131.1% | |
Avg. sales/employee | Rs Th | 4,210.9 | 8,445.4 | 49.9% | |
Avg. wages/employee | Rs Th | 1,132.2 | 2,015.7 | 56.2% | |
Avg. net profit/employee | Rs Th | 191.1 | 891.0 | 21.4% |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 5,710 | 4,907 | 116.4% | |
Other income | Rs m | 123 | 783 | 15.7% | |
Total revenues | Rs m | 5,833 | 5,689 | 102.5% | |
Gross profit | Rs m | 463 | 123 | 377.0% | |
Depreciation | Rs m | 147 | 32 | 463.5% | |
Interest | Rs m | 0 | 16 | 0.0% | |
Profit before tax | Rs m | 438 | 858 | 51.1% | |
Minority Interest | Rs m | 0 | 0 | - | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
Tax | Rs m | 179 | 340 | 52.6% | |
Profit after tax | Rs m | 259 | 518 | 50.0% | |
Gross profit margin | % | 8.1 | 2.5 | 323.9% | |
Effective tax rate | % | 40.8 | 39.6 | 103.0% | |
Net profit margin | % | 4.5 | 10.6 | 43.0% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 3,209 | 8,055 | 39.8% | |
Current liabilities | Rs m | 2,070 | 1,850 | 111.9% | |
Net working cap to sales | % | 20.0 | 126.4 | 15.8% | |
Current ratio | x | 1.6 | 4.4 | 35.6% | |
Inventory Days | Days | 72 | 45 | 160.7% | |
Debtors Days | Days | 35 | 34 | 103.0% | |
Net fixed assets | Rs m | 790 | 150 | 527.6% | |
Share capital | Rs m | 50 | 123 | 40.5% | |
"Free" reserves | Rs m | 2,419 | 7,469 | 32.4% | |
Net worth | Rs m | 2,469 | 7,592 | 32.5% | |
Long term debt | Rs m | 0 | 0 | - | |
Total assets | Rs m | 4,605 | 9,824 | 46.9% | |
Interest coverage | x | NM | 54.9 | - | |
Debt to equity ratio | x | 0 | 0 | - | |
Sales to assets ratio | x | 1.2 | 0.5 | 248.2% | |
Return on assets | % | 5.6 | 5.4 | 103.6% | |
Return on equity | % | 10.5 | 6.8 | 153.9% | |
Return on capital | % | 17.7 | 11.5 | 154.1% | |
Exports to sales | % | 0 | 0 | - | |
Imports to sales | % | 0 | 0 | - | |
Exports (fob) | Rs m | NA | NA | - | |
Imports (cif) | Rs m | NA | NA | - | |
Fx inflow | Rs m | 300 | 58 | 520.1% | |
Fx outflow | Rs m | 2,015 | 1,326 | 151.9% | |
Net fx | Rs m | -1,715 | -1,269 | 135.2% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 88 | -1,943 | -4.5% | |
From Investments | Rs m | -94 | 2,742 | -3.4% | |
From Financial Activity | Rs m | NA | -298 | 0.0% | |
Net Cashflow | Rs m | -6 | 501 | -1.1% |
Indian Promoters | % | 0.0 | 0.0 | - | |
Foreign collaborators | % | 75.0 | 75.0 | 100.0% | |
Indian inst/Mut Fund | % | 0.3 | 2.0 | 15.0% | |
FIIs | % | 15.7 | 1.6 | 981.3% | |
ADR/GDR | % | 0.0 | 0.0 | - | |
Free float | % | 9.1 | 21.5 | 42.3% | |
Shareholders | 12,856 | 41,647 | 30.9% | ||
Pledged promoter(s) holding | % | 0.0 | 0.0 | - |
Compare ASTRAZENECA PHARMA With: TORRENT PHARMA ALKEM LABORATORIES ELDER PHARMA PFIZER DR. DATSONS LABS
Compare ASTRAZENECA PHARMA With: MYLAN (US) ACTAVIS (US) ADCOCK INGRAM (S. Africa) TEVA PHARMA (Israel)
On Tuesday, Indian share markets witnessed volatile trading activity and ended lower.
For the quarter ended December 2020, ASTRAZENECA PHARMA has posted a net profit of Rs 211 m (down 21.2% YoY). Sales on the other hand came in at Rs 2 bn (down 10.5% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.
For the quarter ended June 2020, ASTRAZENECA PHARMA has posted a net profit of Rs 186 m (down 13.4% YoY). Sales on the other hand came in at Rs 2 bn (down 5.4% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.
For the quarter ended March 2020, ASTRAZENECA PHARMA has posted a net profit of Rs 96 m (down 2.5% YoY). Sales on the other hand came in at Rs 2 bn (up 2.4% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.
For the quarter ended December 2019, NOVARTIS has posted a net profit of Rs 77 m (down 39.9% YoY). Sales on the other hand came in at Rs 1 bn (down 13.4% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.
For the quarter ended June 2019, NOVARTIS has posted a net profit of Rs 8 m (down 92.1% YoY). Sales on the other hand came in at Rs 1 bn (down 20.8% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.
More Views on NewsAjit Dayal on how India's vaccine strategy will impact the markets.
In this video I tell you the three Nifty ETFs I think are the best.
Narayana Murthy was one of the first unicorn founders to get the backing of this entity...
There is no stopping this 11-bagger stock from significant upside.
In this video, I'll you what I think is the real reason behind yesterday's market crash.
More